Why Did Buffett Sell the S&P 500?
Warren Buffett has always been an advocate of investing in…
Sell
20
EGRX Quote, Financials, Valuation and Earnings
Last price:
$0.88
Seasonality move
:
11.88%
Day range:
$0.88 - $1.00
52-week range:
$0.00 - $6.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.04x
P/B ratio:
0.05x
Volume:
4K
Avg. volume:
5.3K
1-year change:
-83.21%
Market cap:
$11.4M
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Eagle Pharmaceuticals has 1831.82% upside to fair value with a price target of -- per share.
EGRX vs. S&P 500
-
Over the past 5 trading days, Eagle Pharmaceuticals has underperformed the S&P 500 by -40.02% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Eagle Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Eagle Pharmaceuticals revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Eagle Pharmaceuticals reported revenues of --.
Earnings Growth
-
Eagle Pharmaceuticals earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Eagle Pharmaceuticals reported earnings per share of --.
Enterprise value:
66.3M
EV / Invested capital:
--
Price / LTM sales:
0.04x
EV / EBIT:
1.86x
EV / Revenue:
0.26x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-7.06x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
1.18x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2022-06-30 | 2023-06-30 | |
| Income Statement | ||||||
| Revenue | $189.2M | $272.2M | $257.6M | $74.1M | $64.6M | |
| Gross Profit | $143.1M | $200.2M | $179.9M | $50.5M | $47.8M | |
| Operating Income | $32.3M | $57.8M | $41M | $2.2M | $10.3M | |
| EBITDA | $32.5M | $46.6M | $56.3M | -$3.7M | $16.3M | |
| Diluted EPS | $1.34 | $1.76 | $0.91 | -$0.74 | $0.39 | |
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $185.7M | $168.4M | $175.5M | $194.5M | $187.3M | |
| Total Assets | $261.6M | $256.7M | $264.2M | $381.8M | $404.8M | |
| Current Liabilities | $51.7M | $40.5M | $44.7M | $109M | $86.6M | |
| Total Liabilities | $89.1M | $72.7M | $69.4M | $143.8M | $152.8M | |
| Total Equity | $172.5M | $184M | $194.8M | $238M | $252M | |
| Total Debt | $40.8M | $35.9M | $29.4M | $49.9M | $70.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2022-06-30 | 2023-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $44.5M | $35.5M | -$9.3M | $43M | -$126K | |
| Cash From Investing | -$5.6M | -$75.6M | -$23.8M | -$75.4M | -$6K | |
| Cash From Financing | -$38.3M | -$32M | $11.9M | -$536K | -$6.4M | |
| Free Cash Flow | $43.8M | $35.3M | -$9.4M | $43M | -$132K | |
EGRX
Sector
Market Cap
$11.4M
$36.5M
Price % of 52-Week High
13.82%
44.66%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.9%
1-Year Price Total Return
-83.21%
-39.9%
Beta (5-Year)
0.654
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.20
200-day SMA
Sell
Level
$2.39
Bollinger Bands (100)
Buy
Level
0.59 - 1.15
Chaikin Money Flow
Sell
Level
-6.1K
20-day SMA
Sell
Level
$1.20
Relative Strength Index (RSI14)
Sell
Level
39.85
ADX Line
Sell
Level
14.42
Williams %R
Neutral
Level
-67.3913
50-day SMA
Sell
Level
$1.05
MACD (12, 26)
Buy
Level
0.29
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Sell
Level
-13.7K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
Stock Forecast FAQ
In the current month, EGRX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EGRX average analyst price target in the past 3 months is --.
-
Where Will Eagle Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Eagle Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Eagle Pharmaceuticals?
Analysts are divided on their view about Eagle Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Eagle Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Eagle Pharmaceuticals's Price Target?
The price target for Eagle Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EGRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Eagle Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of EGRX?
You can purchase shares of Eagle Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Eagle Pharmaceuticals shares.
-
What Is The Eagle Pharmaceuticals Share Price Today?
Eagle Pharmaceuticals was last trading at $0.88 per share. This represents the most recent stock quote for Eagle Pharmaceuticals. Yesterday, Eagle Pharmaceuticals closed at $0.88 per share.
-
How To Buy Eagle Pharmaceuticals Stock Online?
In order to purchase Eagle Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will SoundHound AI Stock Recover?
SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…
What Stocks Did Warren Buffett Just Buy?
In Q4 of last year, Warren Buffett added to or…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
Sell
24
AIR alert for Mar 29
AAR [AIR] is down 16.36% over the past day.
